Epizyme, Inc. is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment. Epizyme has two programs in clinical development. Our lead program, EPZ-6438, is in Phase 1/2 development for Non-Hodgkin Lymphoma and a subset of genetically defined tumors including malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas. Epizyme owns worldwide rights to EPZ-6438 outside of Japan, and plans to start a broad Phase 2 clinical development program in 2015. Epizyme‘s management team, scientific advisors, and board of directors are recognized leaders in the scientific community and biopharmaceutical industry. Working together, we are committed to developing novel epigenetic therapeutics for cancer patients. Epizyme is headquartered in Cambridge, MA.

Type
Public
HQ
Cambridge, US
Founded
2007
Employees
89 (est)+4%
Epizyme was founded in 2007 and is headquartered in Cambridge, US

Key People at Epizyme

Jason Rhodes

Jason Rhodes

President and Chief Financial Officer
Eric Hedrick

Eric Hedrick

Chief Medical Officer
Robert Gould

Robert Gould

CEO & Director
Robert A. Copeland

Robert A. Copeland

Executive Vice President and Chief Scientific Officer

Epizyme Locations

Cambridge, US

Epizyme Metrics

Epizyme Summary

Market capitalization

$648 M

Closing share price

$11.1
Epizyme's latest market capitalization is $648 M.

Epizyme Market Value History

25% of current employees of Epizyme are female and 75% are male.

Epizyme Company Life

You may also be interested in